Samuel Aparicio, BM, BCh, PhD, FRCPath FRSC
Nan & Lorraine Robertson Chair in Breast Cancer Research
Canada Research Chair in Molecular Oncology
Distinguished Scientist and Head, Department of Molecular Oncology,
BC Cancer, a part of the Provincial Health Services Authority
Professor, Department of Pathology & Laboratory Medicine
Fellow, Royal Society of Canada, Life Science Division
Decoding the genomic makeup of triple-negative breast cancer that may reveal actionable targets for developing new strategies to personalize therapy.
While platinum-based therapies, like cisplatin, are an effective therapy for many triple-negative breast cancers (TNBCs), new treatments are urgently needed to treat those who do not. One major challenge is that TNBC is a group of diseases that are not fully understood, complicating the development of targeted therapies. Dr. Aparicio's work decoding the genome sequences of TNBC has revealed vulnerabilities that could be used to design effective targeted therapies. Specifically, his team has observed at least four distinct patterns in the DNA structure of TNBC tumors that may represent genomic instabilities and confer deficiencies in the tumors’ ability to repair DNA damage. They are characterizing the processes that lead to these patterns and hope to uncover targets for developing new treatment strategies. These studies could potentially lead to more personalized treatment approaches and improve outcomes for patients with aggressive TNBC.
Dr. Aparicio and his colleagues have identified a new class of drug molecules that exploit genomic instability and repair deficiencies in TNBC tumors. In the last year, they have conducted a phase I clinical study to test one of these drug molecules, CX-5461. Building on their results recently published in the journal Nature, Dr. Aparicio and his team showed that TNBC tumor cells that develop resistance to platinum therapy may be candidates for this novel therapy.
Dr. Aparicio will build on his findings and continue to determine which unique features within the DNA structure increase the susceptibility of TNBC tumors to various agents. CX-5461 has shown promise in early trials and the team will continue to investigate the mechanism of its action and identify additional biomarkers. He hopes this work will lead to future clinical trials to examine DNA characteristics that may identify patients at risk of metastasis. His novel approach leverages a convergence of technologies—such as single cell analysis and translational medicine—bringing expertise from diverse fields to solve a difficult problem, how to recognize and defeat TNBC in the clinic.
Dr. Samuel Aparicio, BM, BCh, PhD, FRCPath is the Nan & Lorraine Robertson Chair in Breast Cancer Research, holds the Canada Research Chair in Molecular Oncology, and is the recipient of the 2014 Aubrey J Tingle Prize. He is also Head of the BCCA’s Department of Breast and Molecular Oncology, and a Professor in the Department of Pathology and Laboratory Medicine at UBC.HE graduated in medicine from Cambridge undertook clinical training in Oxford, subsequently in internal medicine and pathology. After doctoral work with Sydney Brenner in Cambridge he held a Wellcome Trust Career Development Fellowship at the Wellcome/CRUK Developmental Biology Institute. From 2000-2005 he was a senior investigator in the Department of Oncology, Cambridge. He was a co-leader of the international consortium that sequenced the genome of the pufferfish Fugu rubripes in 2002 and a visiting professor at the IMCB, Singapore.
Dr. Aparicio’s research program encompasses the fields of cancer genomics, laboratory genetic models, high throughput screens, small molecule chemical probes and translational breast cancer research. His most recent work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype. Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Contextual Genomics Ltd.
As a physician-scientist, the key philosophy of Dr. Aparicio’s program has been to provide a strong multidisciplinary environment for training of highly qualified personnel (HQP). His former trainees (career total 90) have gone on to success in academia: 1 institute director, 3 as PIs and others in medicine or in senior positions in industry or postgraduate education. All of his graduate students have been successful in securing national (CIHR, NSERC) or provincial (Michael Smith Foundation, CBCF BC/Yukon) competitive salary support and two of the four postdoctoral fellows are supported by independent peer reviewed salary awards from international (Australia), national (CBCF) and provincial (MSFHR) funding bodies.
Dr. Aparicio has published 172 papers in genomics and genetics of disease with >35,000 citations (H-index 77, i10 index 151). He has published in such high impact journals as: New England Journal of Medicine, Nature, Cell, Science, Nature Medicine, Nature Genetics, Nature Methods, Cell Stem Cell and Cell Metabolism.
The Estée Lauder Companies’ North American Research & Development and Manufacturing Award
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.